

# Stapled side-to-side anastomosis versus sutured end-to-end anastomosis following resection for primary or recurrent Crohn's disease

<b>Submission date</b> 09/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 09/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 04/08/2009	<b>Condition category</b> Digestive System	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Robin Susan McLeod

### Contact details

Mount Sinai Hospital  
449-600 University Avenue  
Toronto  
Canada  
M5G 1X5  
+1 416-586-8534  
[rmcleod@mtsinai.on.ca](mailto:rmcleod@mtsinai.on.ca)

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

MCT-50012

# Study information

## Scientific Title

Multicentre randomised controlled trial to compare stapled side-to-side anastomosis with sutured end-to-end anastomosis following resection for primary or recurrent Crohn's disease

## Acronym

CAST (The Canadian and American Surgical Crohn's Disease Trial)

## Study objectives

Patients having an ileocolonic resection for Crohns Disease will have a lower risk of recurrent disease if they have a wide side-to-side anastomosis compared to a end-to-end anastomosis.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Mount Sinai Hospital Research Ethics Board approved on the 28th November 2000

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Crohns disease

## Interventions

Group 1: Hand sewn anastomosis

Group 2: Stapled anastomosis

## Intervention Type

Other

## Phase

Not Applicable

**Primary outcome measure**

Severe endoscopic recurrence at one year follow-up.

**Secondary outcome measures**

1. Symptomatic recurrence (up to 24 months after)
2. Post-operative complication rates
3. Operative times

**Overall study start date**

01/01/2002

**Completion date**

31/07/2005

## Eligibility

**Key inclusion criteria**

1. Women and men aged greater than 16 years
2. Elective ileocolonic resection
3. Colonoscopy and Small Bowel Endoscopy (SBE) completed within the last 3 years
4. Crohns Disease involving the terminal ileum plus or minus right colonic disease
5. No other sites of involvement with Crohns disease in the Gastrointestinal (GI) tract current or past
6. Willing to return for colonoscopy at 12 months

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

200

**Key exclusion criteria**

1. Require emergency surgery
2. Have sites of Crohns involvement elsewhere, except for minimal perianal disease
3. Have had strictureplasties or other resections for Crohns disease performed either at this operation or previously, the exception being resections for fistula disease in bowel not affected by Crohns disease
4. Require a bypass procedure or defunctioning ileostomy during the index procedure
5. Have compromised renal function (serum creatinine level greater than 130 mmol/l or 1.5 mg/l)
6. Prednisone, budesonide, 5-Aminosalicylic Acid (5-ASA) medications, ciprofloxacin,

metronidazole, cyclosporin and Anti-Tumour Necrotising Factor (Anti-TNF) and any other medications used to treat Crohns cannot be discontinued postoperatively  
7. Are unable or willing to give informed consent and return for a colonoscopy at 12 months

**Date of first enrolment**

01/01/2002

**Date of final enrolment**

31/07/2005

## **Locations**

**Countries of recruitment**

Canada

**Study participating centre**

**Mount Sinai Hospital**

Toronto

Canada

M5G 1X5

## **Sponsor information**

**Organisation**

Mount Sinai Hospital (Toronto) (Canada)

**Sponsor details**

600 University Avenue

Toronto

Canada

M5G 1X5

+1 416-586-8348

mmckenzie@mtsinai.on.ca

**Sponsor type**

Not defined

**ROR**

<https://ror.org/05deks119>

## **Funder(s)**

**Funder type**

Charity

### Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-50012)

### Funder Name

Crohns & Colitis Foundation of America (USA)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2009		Yes	No